Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2024,
Kura Oncology received$145.81 Mil more from issuing new shares than it paid to buy back shares.
It received$0.00 Mil from issuing more debt.
It paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It received$2.56 Mil on other financial activities.
In all, Kura Oncologyearned$148.37 Mil on financial activities for the
three
months ended in Mar. 2024.
Kura Oncology Cash Flow from Financing Historical Data
The historical data trend for Kura Oncology's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kura Oncology Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Kura Oncology's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $243.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kura Oncology (NAS:KURA) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Kura Oncology's issuance of stock for the
three
months ended in Mar. 2024 was $145.81 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Kura Oncology's repurchase of stock for the
three
months ended in Mar. 2024 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Kura Oncology's net issuance of debt for the
three
months ended in Mar. 2024 was $0.00 Mil.
Kura Oncology received$0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Kura Oncology's net issuance of preferred for the
three
months ended in Mar. 2024 was $0.00 Mil.
Kura Oncology paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Kura Oncology's cash flow for dividends for the
three
months ended in Mar. 2024 was $0.00 Mil.
Kura Oncology received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Kura Oncology's other financing for the
three
months ended in Mar. 2024 was $2.56 Mil.
Kura Oncology received$2.56 Mil on other financial activities.
Kura Oncology Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Kura Oncology's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Kura Oncology (Kura Oncology) Business Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KURA has been successfully added to your 